Takeda announced the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of lanadelumab for the routine prevention of hereditary angioedema in patients aged two years and older. If approved, lanadelumab will be the first long-term prophylactic treatment available in the EU for patients under the age of six, the company said in a statement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TAK:
- Takeda announces FDA acceptance for review of TAK-721 NDA resubmission
- Takeda announces FDA acceptance for review of its Entyvio BLA
- Takeda commits over $30M in five new global CSR partnerships
- Takeda reports ‘positive’ results from Phase 2b study evaluating TAK-279
- Takeda price target lowered to $14 from $14.20 at JPMorgan